Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza

Vaccine

Volumn 25, Issue 21, 2007, Pages 4283-4290

  Pushko, Peter ^a   Tumpey, Terrence M ^b   Van Hoeven, Neal ^b   Belser, Jessica A ^b   Robinson, Robin ^c   Nathan, Margret ^a   Smith, Gale ^a   Wright, D Craig ^a   Bright, Rick A ^a  

^a NOVAVAX INC   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

Avian influenza virus; Vaccine adjuvants; Virus like particles

Indexed keywords

ADJUVANT; ALUMINUM HYDROXIDE; HEMAGGLUTININ; INFLUENZA VIRUS A H9N2 VIRUS LIKE PARTICLE VACCINE; MATRIX PROTEIN; NOVASOME; RECOMBINANT HEMAGGLUTININ VACCINE; SIALIDASE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AVIAN INFLUENZA; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VIRUS; INFLUENZA VIRUS A H9N2; MALE; MOUSE; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; PROVOCATION TEST; RAT; VIRUS LIKE AGENT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; BODY WEIGHT; DISEASE MODELS, ANIMAL; FEMALE; FERRETS; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H9N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, TRANSMISSION; RATS; SPODOPTERA; VACCINES, SYNTHETIC; VIROSOMES;

EID: 34247544288     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.02.059     Document Type: Article

References (25)

1. Pushko P., Tumpey T.M., Fang Bu, Knell J., Robinson R., and Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 23 50 (2005) 5751-5759
2. Horimoto T., and Kawaoka Y. Pandemic threat posed by avian influenza A viruses. Clin Microbiol Rev 14 1 (2001) 129-149
3. Stephenson I., Nicholson K.G., Wood J.M., Zambon M.C., and Katz J.M. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis 4 8 (2004) 499-509
4. Smith D.J. Predictability and preparedness in influenza control. Science 312 5772 (2006) 392-394
5. Webby R.J., and Webster R.G. Are we ready for pandemic influenza?. Science 302 5650 (2003) 1519-1522
6. CDC. Update: Influenza Activity-United States and Worldwide, 2005-06 Season, and Composition of the 2006-07 Influenza Vaccine 2006;55:648-53.
7. Maines T.R., Lu X.H., Erb S.M., Edwards L., Guarner J., Greer P.W., et al. Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol 79 18 (2005) 11788-11800
8. Peiris M., Yuen K.Y., Leung C.W., Chan K.H., Ip P.L., Lai R.W., et al. Human infection with influenza H9N2. Lancet 354 9182 (1999) 916-917
9. Choi Y.K., Ozaki H., Webby R.J., Webster R.G., Peiris J.S., Poon L., et al. Continuing Evolution of H9N2 Influenza Viruses in Southeastern China. J Virol 78 16 (2004) 8609-8614
10. Chambers M.A., Wright D.C., Brisker J., Williams A., Hatch G., Gavier-Widen D., et al. A single dose of killed Mycobacterium bovis BCG in a novel class of adjuvant (Novasome) protects guinea pigs from lethal tuberculosis. Vaccine 22 8 (2004) 1063-1071
11. Bramwell V.W., and Perrie Y. Particulate delivery systems for vaccines. Crit Rev Ther Drug Carrier Syst 22 2 (2005) 151-214
12. Pumpens P., and Grens E. Artificial genes for chimeric virus-like particles. In: Khudyakov Y.E., and Fields H.A. (Eds). Artificial DNA (2003), CRC Press, New York 249-327
13. Wood J.M., Schild G.C., Newman R.W., and Seagroatt V. Application of an improved single-radial-immunodiffusion technique for the assay of haemagglutinin antigen content of whole virus and subunit influenza vaccines. Dev Biol Stand 39 (1977) 193-200
14. In: Kendal A.P., Skehel J.J., and Pereira M. (Eds). World Health Organization Collaborating Centers for reference and research on influenza. Concepts and procedures for laboratory-based influenza surveillance (1982), Centers for Disease Control and Prevention, Atlanta B17-B35
15. Lu X., Renshaw M., Tumpey T.M., Kelly G.D., Hu-Primmer J., and Katz J.M. Immunity to influenza A H9N2 viruses induced by infection and vaccination. J Virol 75 10 (2001) 4896-4901
16. Mozdzanowska K., Furchner M., Washko G., Mozdzanowski J., and Gerhard W. A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. J Virol 71 6 (1997) 4347-4355
17. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 37 4 (1999) 937-943
18. Crawford J., Wilkinson B., Vosnesensky A., Smith G., Garcia M., Stone H., et al. Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes. Vaccine 17 18 (1999) 2265-2274
19. Treanor J.J., Wilkinson B.E., Masseoud F., Hu-Primmer J., Battaglia R., O'Brien D., et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19 13-14 (2001) 1732-1737
20. Galarza J.M., Latham T., and Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol 18 1 (2005) 244-251
21. Guy B., and Burdin N. New adjuvants for parenteral and mucosal vaccines. Therapie 60 3 (2005) 235-241
22. Skea D.L., and Barber B.H. Adhesion-mediated enhancement of the adjuvant activity of alum. Vaccine 11 10 (1993) 1018-1026
23. Deroo T., Jou W.M., and Fiers W. Recombinant neuraminidase vaccine protects against lethal influenza. Vaccine 14 6 (1996) 561-569
24. Plotnicky H., Cyblat-Chanal D., Aubry J.P., Derouet F., Klinguer-Hamour C., Beck A., et al. The immunodominant influenza matrix T cell epitope recognized in human induces influenza protection in HLA-A2/K(b) transgenic mice. Virology 309 2 (2003) 320-329
25. Okuda K., Ihata A., Watabe S., Okada E., Yamakawa T., Hamajima K., et al. Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. Vaccine 19 27 (2001) 3681-3691